<?xml version="1.0" ?>
<akomaNtoso xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">
  <act name="section">
    <meta>
      <identification source="#wa-legislature">
        <FRBRWork>
          <FRBRthis value="/us-wa/act/rcw/74.09.559"/>
          <FRBRuri value="/us-wa/act/rcw/74.09.559"/>
          <FRBRdate date="2025-12-31" name="enacted"/>
          <FRBRauthor href="#wa-legislature"/>
          <FRBRcountry value="us-wa"/>
        </FRBRWork>
        <FRBRExpression>
          <FRBRthis value="/us-wa/act/rcw/74.09.559/eng"/>
          <FRBRuri value="/us-wa/act/rcw/74.09.559/eng"/>
          <FRBRdate date="2025-12-31" name="publication"/>
          <FRBRauthor href="#wa-legislature"/>
          <FRBRlanguage language="eng"/>
        </FRBRExpression>
        <FRBRManifestation>
          <FRBRthis value="/us-wa/act/rcw/74.09.559/eng/akn"/>
          <FRBRuri value="/us-wa/act/rcw/74.09.559/eng/akn"/>
          <FRBRdate date="2025-12-31" name="generation"/>
          <FRBRauthor href="#cosilico"/>
        </FRBRManifestation>
      </identification>
      <references source="#cosilico">
        <TLCOrganization eId="wa-legislature" href="/ontology/organization/us-wa/legislature" showAs="Washington State Legislature"/>
        <TLCOrganization eId="cosilico" href="https://cosilico.ai" showAs="Cosilico"/>
      </references>
    </meta>
    <body>
      <section eId="sec_74_09_559">
        <num>RCW 74.09.559</num>
        <heading>Long-acting injectable buprenorphine—Billing codes—Reimbursement</heading>
        <subsection eId="sec_74_09_559__subsec_1">
          <num>(1)</num>
          <content>
            <p>The authority shall establish appropriate billing codes for hospitals and psychiatric hospitals that administer long-acting injectable buprenorphine on an outpatient basis to use for billing patients enrolled in a medical assistance program.</p>
          </content>
        </subsection>
        <subsection eId="sec_74_09_559__subsec_2">
          <num>(2)</num>
          <content>
            <p>Upon initiation or renewal of a contract with the authority to administer a medicaid managed care plan, a managed care organization must reimburse a hospital or psychiatric hospital that bills for the administration of long-acting injectable buprenorphine on an outpatient basis as a separate reimbursable expense.</p>
          </content>
        </subsection>
        <subsection eId="sec_74_09_559__subsec_3">
          <num>(3)</num>
          <content>
            <p>Beginning January 1, 2025, for individuals enrolled in a medical assistance program that is not a medicaid managed care plan, the authority must reimburse a hospital or psychiatric hospital that bills for the administration of long-acting injectable buprenorphine on an outpatient basis administered as a separate reimbursable expense.</p>
          </content>
        </subsection>
        <subsection eId="sec_74_09_559__subsec_4">
          <num>(4)</num>
          <content>
            <p>Reimbursements provided under this section must be separate from any bundled payment for outpatient hospital or emergency department services.
[
2024 c 366 s 18
.]
NOTES:
Findings
—
Intent
—
2024 c 366:
See note following RCW
71.24.847
.</p>
          </content>
        </subsection>
      </section>
    </body>
  </act>
</akomaNtoso>
